Literature DB >> 22383356

Psoriasis onset with tocilizumab treatment for rheumatoid arthritis.

Daniel Wendling, Hélène Letho-Gyselinck, Xavier Guillot, Clément Prati.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22383356     DOI: 10.3899/jrheum.111166

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  19 in total

1.  Is tocilizumab safe in Kaposi sarcoma? A complex association among rheumatoid arthritis, psoriasis, and Kaposi sarcoma.

Authors:  Alice Verdelli; Diletta Bonciani; Veronica Bonciolini; Marzia Caproni
Journal:  Clin Drug Investig       Date:  2014-06       Impact factor: 2.859

2.  Induction of Alternative Proinflammatory Cytokines Accounts for Sustained Psoriasiform Skin Inflammation in IL-17C+IL-6KO Mice.

Authors:  Yi Fritz; Philip A Klenotic; William R Swindell; Zhi Qiang Yin; Sarah G Groft; Li Zhang; Jaymie Baliwag; Maya I Camhi; Doina Diaconu; Andrew B Young; Alexander M Foster; Andrew Johnston; Johann E Gudjonsson; Thomas S McCormick; Nicole L Ward
Journal:  J Invest Dermatol       Date:  2016-10-27       Impact factor: 8.551

3.  Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience.

Authors:  Rahul Sehgal; Erik J Stratman; Jonathan E Cutlan
Journal:  Clin Med Res       Date:  2018-04-02

Review 4.  Cutaneous Manifestations of Reactions to Biologics.

Authors:  Iris M Otani; Amy S Levin; Aleena Banerji
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-21       Impact factor: 4.806

5.  Inflammation-Induced IL-6 Functions as a Natural Brake on Macrophages and Limits GN.

Authors:  Michael Luig; Malte A Kluger; Boeren Goerke; Matthias Meyer; Anna Nosko; Isabell Yan; Jürgen Scheller; Hans-Willi Mittrücker; Stefan Rose-John; Rolf A K Stahl; Ulf Panzer; Oliver M Steinmetz
Journal:  J Am Soc Nephrol       Date:  2015-02-05       Impact factor: 10.121

Review 6.  Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review.

Authors:  Michitaro Hayakawa; Keisuke Izumi; Misako Higashida-Konishi; Mari Ushikubo; Masako Tsukamoto; Kumiko Akiya; Kazuhiro Araki; Hisaji Oshima
Journal:  Rheumatol Int       Date:  2018-10-24       Impact factor: 2.631

7.  Interleukin 6 regulates psoriasiform inflammation-associated thrombosis.

Authors:  Yunmei Wang; Jackelyn B Golden; Yi Fritz; Xiufen Zhang; Doina Diaconu; Maya I Camhi; Huiyun Gao; Sean M Dawes; Xianying Xing; Santhi K Ganesh; Johann E Gudjonsson; Daniel I Simon; Thomas S McCormick; Nicole L Ward
Journal:  JCI Insight       Date:  2016-12-08

Review 8.  The Changing Landscape of Renal Inflammation.

Authors:  Thomas Ernandez; Tanya Norton Mayadas
Journal:  Trends Mol Med       Date:  2016-01-07       Impact factor: 11.951

9.  Inhibition of interleukin-6 on matrix protein production by glomerular mesangial cells and the pathway involved.

Authors:  Sarika Chaudhari; Parisa Yazdizadeh Shotorbani; Yu Tao; Mark E Davis; Robert T Mallet; Rong Ma
Journal:  Am J Physiol Renal Physiol       Date:  2020-05-11

10.  E3 ubiquitin ligase NEDD4L negatively regulates keratinocyte hyperplasia by promoting GP130 degradation.

Authors:  Huan Liu; Wenlong Lin; Zhiyong Liu; Yinjing Song; Hao Cheng; Huazhang An; Xiaojian Wang
Journal:  EMBO Rep       Date:  2021-03-26       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.